Patents Assigned to Ardian, Inc.
-
Publication number: 20070203549Abstract: Methods and apparatus are provided for pulsed electric field neuromodulation via an intra-to-extravascular approach, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation and other conditions in target neural fibers. In some embodiments, the ITEV PEF system comprises an intravascular catheter having one or more electrodes configured for intra-to-extravascular placement across a wall of patient's vessel into proximity with target neural fibers. With the electrode(s) passing from an intravascular position to an extravascular position prior to delivery of the PEF, a magnitude of applied voltage or energy delivered via the electrode(s) and necessary to achieve desired neuromodulation may be reduced relative to an intravascular PEF system having one or more electrodes positioned solely intravascularly.Type: ApplicationFiled: February 27, 2006Publication date: August 30, 2007Applicant: Ardian, Inc.Inventors: Denise Demarais, Benjamin Clark, Nicolas Zadno, Erik Thai, Hanson Gifford
-
Publication number: 20070173899Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.Type: ApplicationFiled: March 19, 2007Publication date: July 26, 2007Applicant: Ardian, Inc.Inventors: Howard Levin, Mark Gelfand
-
Publication number: 20070135875Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues. In some embodiments, thermally-induced renal neuromodulation is achieved via delivery of a pulsed thermal therapy.Type: ApplicationFiled: November 14, 2006Publication date: June 14, 2007Applicant: Ardian, Inc.Inventors: Denise Demarais, Andrew Wu, Hanson Gifford, Mark Deem
-
Publication number: 20070129720Abstract: Methods and apparatus are provided for non-continuous circumferential treatment of a body lumen. Apparatus may be positioned within a body lumen of a patient and may deliver energy at a first lengthwise and angular position to create a less-than-full circumferential treatment zone at the first position. The apparatus also may deliver energy at one or more additional lengthwise and angular positions within the body lumen to create less-than-full circumferential treatment zone(s) at the one or more additional positions that are offset lengthwise and angularly from the first treatment zone. Superimposition of the first treatment zone and the one or more additional treatment zones defines a non-continuous circumferential treatment zone without formation of a continuous circumferential lesion. Various embodiments of methods and apparatus for achieving such non-continuous circumferential treatment are provided.Type: ApplicationFiled: November 14, 2006Publication date: June 7, 2007Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, Mark Deem, Nicolas Zadno, Benjamin Clark, Andrew Wu, Kenneth Michlitsch
-
Publication number: 20070129760Abstract: Methods and apparatus are provided for intravascularly-induced neuromodulation or denervation. Neuromodulation may be achieved via direct and/or via indirect application of energy or neuromodulatory agents to target neural matter, or to vascular structures that support the target neural matter. In some embodiments, parameters of the target neural matter, of non-target tissue, or of the apparatus may be monitored via one or more sensors for controlling the neuromodulation or denervation. Such monitoring data optionally may be utilized for feedback control of the neuromodulation or denervation.Type: ApplicationFiled: November 14, 2006Publication date: June 7, 2007Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, Mark Deem, Douglas Sutton, Erik Thai, Benjamin Clark, Nicolas Zadno
-
Publication number: 20070129761Abstract: Methods and apparatus are provided for treatment of heart arrhythmia via renal neuromodulation. Such neuromodulation may effectuate irreversible electroporation or electrofusion, ablation, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, such neuromodulation is achieved through application of an electric field. In some embodiments, such neuromodulation is achieved through application of neuromodulatory agents, of thermal energy and/or of high intensity focused ultrasound. In some embodiments, such neuromodulation is performed in a bilateral fashion.Type: ApplicationFiled: November 14, 2006Publication date: June 7, 2007Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford
-
Publication number: 20070066957Abstract: Methods and apparatus are provided for inducing, monitoring and controlling renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. In some embodiments, tissue impedance, conductance or conductivity may be monitored to determine the effects of pulsed electric field therapy, e.g., to determine an extent of electroporation and its degree of irreversibility. Pulsed electric field electroporation of tissue causes a decrease in tissue impedance and an increase in tissue conductivity. If induced electroporation is reversible, upon cessation of the pulsed electric field, tissue impedance and conductivity should approximate baseline levels; however, if electroporation is irreversible, impedance and conductivity changes should persist. Thus, monitoring of impedance or conductivity may be utilized to determine the onset of electroporation and to determine the type or extent of electroporation.Type: ApplicationFiled: October 18, 2005Publication date: March 22, 2007Applicant: Ardian, Inc.Inventors: Denise Demarais, Nicolas Zadno
-
Patent number: 7162303Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.Type: GrantFiled: April 8, 2003Date of Patent: January 9, 2007Assignee: Ardian, Inc.Inventors: Howard R. Levin, Mark Gelfand
-
Publication number: 20060276852Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: ApplicationFiled: March 6, 2006Publication date: December 7, 2006Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, Mark Deem, Douglas Sutton, Howard Levin, Mark Gelfand
-
Publication number: 20060271111Abstract: Methods and apparatus are provided for treating contrast nephropathy, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: ApplicationFiled: March 6, 2006Publication date: November 30, 2006Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, Mark Deem, Douglas Sutton
-
Publication number: 20060265015Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.Type: ApplicationFiled: April 13, 2006Publication date: November 23, 2006Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, Mark Deem, Howard Levin, Mark Gelfand, US Zadno
-
Publication number: 20060265014Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: ApplicationFiled: March 6, 2006Publication date: November 23, 2006Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, Mark Deem, Douglas Sutton, Howard Levin, Mark Gelfand
-
Publication number: 20060235474Abstract: Methods and apparatus are provided for multi-vessel neuromodulation, e.g., via a pulsed electric field. Such multi-vessel neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, the multi-vessel neuromodulation is applied to neural fibers that contribute to renal function. Such multi-vessel neuromodulation optionally may be performed bilaterally.Type: ApplicationFiled: June 12, 2006Publication date: October 19, 2006Applicant: Ardian, Inc.Inventor: Denise Demarais
-
Publication number: 20060212076Abstract: Methods and apparatus are provided for treating end-stage renal disease, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: ApplicationFiled: March 6, 2006Publication date: September 21, 2006Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, Mark Deem, Douglas Sutton, Howard Levin, Mark Gelfand
-
Publication number: 20060212078Abstract: Methods and apparatus are provided for treating congestive heart failure, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: ApplicationFiled: March 6, 2006Publication date: September 21, 2006Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, Mark Deem, Douglas Sutton, Howard Levin, Mark Gelfand
-
Publication number: 20060206150Abstract: Methods and apparatus are provided for treating acute myocardial infarction, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: ApplicationFiled: March 6, 2006Publication date: September 14, 2006Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, Mark Deem, Douglas Sutton, Howard Levin, Mark Gelfand
-
Publication number: 20060142801Abstract: Methods and apparatus are provided for intravascularly-induced neuromodulation using a pulsed electric field, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation, etc., in target neural fibers. In some embodiments, the intravascular PEF system comprises a catheter having a pair of bipolar electrodes for delivering the PEF, with a first electrode positioned on a first side of an impedance-altering element and a second electrode positioned on an opposing side of the impedance-altering element. A length of the electrodes, as well as a separation distance between the first and second electrodes, may be specified such that, with the impedance-altering element deployed in a manner that locally increases impedance within a patient's vessel, e.g.Type: ApplicationFiled: November 4, 2005Publication date: June 29, 2006Applicant: Ardian, Inc.Inventors: Denise Demarais, Nicolas Zadno, Benjamin Clark, Erik Thai
-
Patent number: 6978174Abstract: A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump eluting implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.Type: GrantFiled: July 28, 2004Date of Patent: December 20, 2005Assignee: Ardian, Inc.Inventors: Mark Gelfand, Howard R. Levin